Ocean Biomedical Corp (OCEA) - Long-Term Debt to Capital Coefficient

Ocean Biomedical, Inc. (OCEA) focuses on the commercialization of advanced treatments for oncology, malaria, and pulmonary pathologies through licensing agreements and royalties. The company minimizes risks by implementing developments from leading universities across parallel projects. This market valuation chart on GURU.Markets captured a figure of 0.00. Currently, the business lacks stable cash flows and operates through the gradual utilization of investment capital.

Ocean Biomedical, Inc. (OCEA) maintains a stable legal status due to the humanitarian protections afforded to medicine in the US. By analyzing the long-term debt-to-net assets ratio, an investor assesses the proportion of liabilities with a maturity of over one year relative to equity. This metric determines the balance between financial leverage and the company's solvency. While a decrease in this ratio minimizes risks, a complete avoidance of borrowing may slow growth rates. The market views a moderate debt load as a guarantee of stable development.